

Remarks

Currently Claims 22-25 are pending. Claims 1-21 have been canceled. Claims 1, 5 and 7 are re-written as new claims 22-25. No new matter is added.

The specification has been amended to recite cross-references to related applications and to provide an abstract on a separate page.

An IDS and PTO-1449 is submitted concurrently herewith.

Applicants respectfully submit that the instant application is in condition for substantive examination, which action is respectfully requested. The Examiner is invited to contact the undersigned at (919) 483-8222, to discuss this case further if desired.

Respectfully submitted,



Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 25 February, 2004
GlaxoSmithKline Inc.
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988

Abstract

The invention provides a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof for use in the treatment of a disorder ameliorated by a gastroprokinetic.